SRTS
Sensus Healthcare, Inc.
SRTS trails on the overall score without a compensating advantage in the available component scores.
UNH
UnitedHealth Group Incorporated
UNH has the edge over SRTS overall, supported by stronger fundamentals and lower modeled downside.
SRTS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
SRTS's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
SRTS PE Valuation
SRTS has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
SRTS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Decline | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect SRTS's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
UNH has the edge over SRTS on the outlook, with more favorable revenue expectations.
SRTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.94 | -$0.89 |
| Q1 2026 | -$0.47 | -527% |
| Q4 2025 | -$0.47 | -215% |
SRTS lost $0.94 per share over the past year, a bigger loss than the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over SRTS in the latest year-over-year earnings comparison.
SRTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $6M | -13% |
| Q2 2026 | $2.3M | -69% |
| Q1 2026 | $3.4M | -59% |
| Q4 2025 | $4.9M | -62% |
SRTS's revenue has slid since its 2024 peak: $6M last quarter, down 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -139% | -112 points |
| Q1 2026 | -128% | -97 points |
| Q4 2025 | -64% | -77 points |
| Q3 2025 | -37% | N/A |
| Q2 2025 | -27% | N/A |
| Q1 2025 | -32% | N/A |
| Q4 2024 | 13% | N/A |
SRTS's operating margin was −139% last quarter, down 112 points from the same quarter a year ago, near the bottom of its range since 2024.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over SRTS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over SRTS on profitability, with a higher operating margin.
SRTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.1M | -202% |
| Q1 2026 | -$3.8M | -$1.1M |
| Q4 2025 | -$2.4M | -$1.8M |
UNH has the edge over SRTS in the latest year-over-year cash flow comparison.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over SRTS in the latest year-over-year cash flow comparison.
SRTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -594 shares |
| 1 year | +0.9% | +142K shares |
SRTS has 16M diluted shares, up 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $300,000 |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over SRTS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
SRTS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2025 | -6.8x | Net Cash |
| Q4 2024 | -2.7x | Net Cash |
SRTS has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
SRTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.3 | Neutral |
| Stochastic | 11.9 | Oversold |
SRTS's weekly RSI is 51 (neutral) and its Stochastic is 12 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
SRTS PE vs Healthcare Sector
| Metric | SRTS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SRTS has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
SRTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.93 | 9.9% above |
| 20 week MA | $3.03 | 6.3% above |
| 50 week MA | $3.57 | 9.8% below |
| 100 week MA | $4.12 | 22% below |
| 200 week MA | $4.35 | 26% below |
SRTS has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 26% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over SRTS on trend strength, trading above more of its moving averages.
SRTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.38 | $3.91 | +16% |
| 2021 | $3.91 | $8.34 | +113% |
| 2022 | $8.34 | $6.90 | -17% |
| 2023 | $6.90 | $2.36 | -66% |
| 2024 | $2.36 | $7.21 | +206% |
| 2025 | $7.21 | $3.79 | -47% |
| 2026 YTD | $3.79 | $3.22 | -15% |
SRTS's yearly returns have swung widely, from +206% in 2024 to −66% in 2023. It's down 15% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over SRTS on returns for 2026, with the stronger performance.